Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

Li Tang; Diego R Hijano; Aditya H Gaur; Terrence L Geiger; Ellis J Neufeld; James M Hoffman; Randall T Hayden

doi:10.1001/jama.2021.6564

Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce

JAMA. 2021 Jun 22;325(24):2500-2502. doi: 10.1001/jama.2021.6564.

Authors

Li Tang¹, Diego R Hijano², Aditya H Gaur², Terrence L Geiger³, Ellis J Neufeld⁴, James M Hoffman⁵, Randall T Hayden³

Affiliations

¹ Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee.
² Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee.
³ Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee.
⁴ Department of Hematology, St Jude Children's Research Hospital, Memphis, Tennessee.
⁵ Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee.

Abstract

This study aims to describe an association between the Pfizer-BioNTech (BNT162b2) vaccine and decreased risk of symptomatic and asymptomatic infections with SARS-CoV-2 in hospital employees.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Asymptomatic Infections / epidemiology
BNT162 Vaccine
COVID-19 / diagnosis
COVID-19 / epidemiology*
COVID-19 / prevention & control
COVID-19 Vaccines*
Female
Humans
Male
Mass Screening
Middle Aged
Personnel, Hospital*
Retrospective Studies

Substances

COVID-19 Vaccines
BNT162 Vaccine